Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA appropriations

This article was originally published in The Tan Sheet

Executive Summary

House Appropriations/agriculture subcommittee more than doubles FDA's budget for buildings and facilities from $8.4 mil. in FY 94 to just over $18 mil. in FY 95 at a May 26 budget markup. The increase is intended to cover the cost of replacing the agency's Los Angeles laboratory, which Chairman Richard Durbin (D-Ill.) called a "disaster" and a "dangerous place to work." The committee also provided FDA with $79 mil. in Rx user fees, consistent with funding levels authorized by the 1992 Prescription Drug User Fee Act, but only a fraction of the $343 mil. in user fees requested in the administration's FY 95 proposed budget. The subcommittee set the total level of FDA funding at $914 mil. plus user fees. In 1994, net government outlays were $873 mil. plus $61 mil. in user fee collections, for total funding of $934 mil

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel